Navigation Links
MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates

GERMANTOWN, Md., Nov. 3 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has retained national account firm VCG & Associates. VCG & Associates will serve as MiddleBrook's strategic and tactical managed care partner, assisting in product pricing and reimbursement, contract administration, national account management and government account coverage.

President and CEO John Thievon said, "VCG & Associates has mirrored MiddleBrook's excitement regarding the upcoming launch of MOXATAG, the first and only FDA-approved once-daily amoxicillin, and it's clear they have a strong commitment to the launch's success."

Thievon continued, "While our professional field force will champion the advantages of MOXATAG over currently available amoxicillin therapies with healthcare practitioners across the nation, VCG & Associates will lead the charge to inform and engage managed care organizations, as well as government and non-retail outlets throughout the country. This is an exciting alliance for MiddleBrook."


MOXATAG (extended-release amoxicillin) 775mg tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit

About VCG & Associates:

VCG & Associates, Inc. is an independent strategic marketing and contract national account organization specializing in the commercialization of pharmaceutical, biotech, and medical device products. VCG & Associates has successfully brought together a select combination of industry experts to cover the spectrum of product entry into the US market. The company's core area of expertise can be divided into two categories; strategic planning and active field execution. Strategic planning activities include market research, pricing and reimbursement, strategic planning, commercialization planning, and launch plans. Field execution activities include: trade support, contracting administration, national account management, and government account coverage.

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential," "estimate," "will," "may," "predict," "should," "could," "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors," in our Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 17, 2008, and in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31, 2007 and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. MiddleBrook, MiddleBrook Pharmaceuticals, Inc., PULSYS, MOXATAG and Keflex are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademark applications. Each of the other trademarks, tradenames or services marks appearing in this document belongs to its respective holder.

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
2. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
3. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
4. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
8. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
9. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
10. Genesis Pharmaceuticals Files Counter Claims
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... the United States to access life-saving information provided directly from top experts ... consist of three individual conferences in three major cities: Houston, San Francisco, and ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... its annual fundraising campaign to raise funds for its research, education, support, and ... of the organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also ...
(Date:11/30/2015)... Wilmington, DE (PRWEB) , ... November 30, 2015 ... ... a guest lecturer at a University of Delaware Accounting and Management of Information ... accounting software solutions for mid-market businesses. Sommer will speak at before student in ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Progressive Dental Institute ... January 29 and 30, 2016. The course welcomes dental professionals and members of ... learn how to better succeed in the modern dental marketplace. The course combines ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the ... organized by the Baruch S. Blumberg Institute. , The institute, which is the research ... science and biotechnology leaders for the conference, which focused on ways companies can work ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... INDIANAPOLIS , Nov. 30, 2015  PTS Diagnostics, ... as CardioChek ® analyzers, A1CNow ® systems, ... of a family of patents that will propel the ... and Europe . The ... cameras, such as those on smartphones and tablets, and ...
(Date:11/30/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), ... oral drug delivery systems, announced today it has signed ... Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT") for exclusive ... China , Hong Kong ... agreements were signed at the Israel Knesset (Parliament). ...
Breaking Medicine Technology: